Report interim biomarker data from the nfvPPA clinical trial

Deadline not yet reached (65 days left)

What the company said

“interim biomarker data is anticipated in the early fourth quarter of 2026”

SourceCervoMed Inc. Form 8-K press release, 2026-09-28
FilingSEC filing index
Deadline as statedearly fourth quarter of 2026
Deadline used31 Dec 2026, the last day of the stated period
TypeProject
Permanent referenceKI-C-2026-CRVO-000882
Cite as https://keptindex.org/c/KI-C-2026-CRVO-000882/ — this address never changes.

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2026.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 28 Sep 2026

Deadline 31 Dec 2026 (“early fourth quarter of 2026”) · wording expected
Version 2 · stated 13 Oct 2026

Deadline 31 Mar 2027 (“in the first quarter of 2027”) · wording expected

“clinical data expected in the first quarter of 2027”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you CervoMed Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.